Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00000828
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
Study of Perinatal Transmission of Zidovudine-Resistant HIV Among Pregnant Women Treated With Zidovudine
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institute of Allergy and Infectious Diseases NIAID
Study Overview
Official Title:
Study of Perinatal Transmission of Zidovudine-Resistant HIV Among Pregnant Women Treated With Zidovudine
Status:
COMPLETED
Status Verified Date:
1997-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To identify patterns of zidovudine AZT susceptibility among motherinfant pairs with perinatal HIV transmission
Most HIV-infected infants acquire their disease via perinatal transmission Since transmission of HIV-resistant strains to infants could alter the course of disease and response to currently recommended treatment a study to assess the patterns of AZT susceptibility among motherinfant pairs with perinatal transmission is essential to delineate future therapeutic strategies
Most HIV-infected infants acquire their disease via perinatal transmission Since transmission of HIV-resistant strains to infants could alter the course of disease and response to currently recommended treatment a study to assess the patterns of AZT susceptibility among motherinfant pairs with perinatal transmission is essential to delineate future therapeutic strategies
Detailed Description:
Most HIV-infected infants acquire their disease via perinatal transmission Since transmission of HIV-resistant strains to infants could alter the course of disease and response to currently recommended treatment a study to assess the patterns of AZT susceptibility among motherinfant pairs with perinatal transmission is essential to delineate future therapeutic strategies
HIV-infected pregnant women are enrolled at 20-36 weeks gestation Patients have blood drawn for HIV culture at study entry and at delivery Infants have blood drawn for HIV culture at delivery and at 1 3 6 and 18 months of age
HIV-infected pregnant women are enrolled at 20-36 weeks gestation Patients have blood drawn for HIV culture at study entry and at delivery Infants have blood drawn for HIV culture at delivery and at 1 3 6 and 18 months of age
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: